Effect of Oral Administration of Mytragina Speciosa on Blood Ketone Level and Glomerular Histology in Streptozotocin Induced Diabetic Mice
Article Sidebar
Main Article Content
Abstract
Introduction: Diabetes mellitus is a chronic metabolic disease characterized by increased sugar levels that cause serious damage to various organs. Diabetic ketoacidosis is one of the complications of diabetes mellitus. It is characterized by a decrease in the patient's consciousness, increased blood sugar levels, and the presence of acidic ketone bodies. It is a serious condition that can cause a coma or even death. Mytragina Speciosa, known as kratom, is a plant often found in Southeast Asia, including Indonesia. This herb is frequently used as a stimulant to treat fatigue and help improve productivity. Based on previous research, Mytragina Speciosa is rich in alkaloids, flavonoids, and phenols. These compounds are very useful for inhibiting the activity of α-glucosidase and lipase enzymes in the pancreas, so they have a potential effect on diabetes mellitus. However, there has been no research related to the administration of Mytragina Speciosa its effect on blood ketone levels and glomerular diameter.
Objective: to determine whether there is an effect of Mytragina Speciosa on blood ketone levels and glomerular diameter in mice with a diabetes mellitus model.
Methods: Hyperglycemia is induced by Streptozotocin. On the 14th day, the mice will be checked for hyperglycemia and blood ketone levels. Administration of Mytragina Speciosa begins on day 15 for 2 weeks. At the end of the second week, the mice will be checked for blood ketone levels using a special kit to detect ketone bodies. Furthermore, the glomerular diameter will also be assessed.
Results: In this study, treatment for 2 weeks only caused an increase in blood sugar levels in mice, but did not cause an increase in blood ketone levels in the diabetes group or other treatment groups (p > 0.05). Histological preparation of the Glomerulus showed a decline in glomerular diameter.
Conclusions: The administration of Mitragyna speciosa extract did not result in a significant increase in blood ketone levels in diabetic mice. Many factors are involved in increasing blood ketone. It is necessary to monitor ketone levels during treatment as well as have a longer treatment time to see the effect of Mitragyna speciosa on ketones
Downloads
Article Details
Copyright (c) 2024 Choirotussanijjah choirotussanijjah, Hotimah Masdan Salim, Tri Wahyuni Bintarti, Danny Irawan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
Adair R Gosmanov, M.D., Ph.D., F.A.C.E. and Abbas E Kitabchi, M.D., Ph.D., M. A. C. 2018. Diabetic Ketoacidosis. in (2018).
Boulton, A. J. M., Vileikyte, L., Ragnarson-Tennvall, G. & Apelqvist, J. 2005. The global burden of diabetic foot disease. Lancet (London, England) 366, 1719–1724 (2005). DOI: https://doi.org/10.1016/S0140-6736(05)67698-2
BPPK Kemenkeu. 2022. DAUN SURGA ASAL KALIMANTAN ANTARA KHASIAT DAN LEGALITAS. https://bppk.kemenkeu.go.id/balai-diklat-keuangan-pontianak/artikel/daun-surga-asal-kalimantan-antara-khasiat-dan-legalitas-360775 (2022).
CDC. 2022. Diabetic Ketoacidosis. https://www.cdc.gov/diabetes/basics/diabetic-ketoacidosis.html (2022).
Charoenratana, S., Anukul, C. & Aramrattana, A. 2021. Attitudes towards Kratom use, decriminalization and the development of a community-based Kratom control mechanism in Southern Thailand. Int. J. Drug Policy 95, 103197 (2021). DOI: https://doi.org/10.1016/j.drugpo.2021.103197
Chatterjee, S., Khunti, K. & Davies, M. J. 2017. Type 2 diabetes. Lancet (London, England) 389, 2239–2251 (2017) DOI: https://doi.org/10.1016/S0140-6736(17)30058-2
Eastlack, S. C., Cornett, E. M. & Kaye, A. D. 2020. Kratom-Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review. Pain Ther. 9, 55–69 (2020). DOI: https://doi.org/10.1007/s40122-020-00151-x
Goh, Y. S. et al. 2021. Accelerated Solvent Extractions (ASE) of Mitragyna speciosa Korth. (Kratom) Leaves: Evaluation of Its Cytotoxicity and Antinociceptive Activity. Molecules 26, (2021). DOI: https://doi.org/10.3390/molecules26123704
Hamdy, O. 2021. Diabetic Ketoacidosis (DKA). https://emedicine.medscape.com/article/118361-overview (2021).
Hassan, Z. et al. 2013. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neurosci. Biobehav. Rev. 37, 138–151 (2013). DOI: https://doi.org/10.1016/j.neubiorev.2012.11.012
Kanikarla-Marie, P. & Jain, S. K. 2016. Hyperketonemia and ketosis increase the risk of complications in type 1 diabetes. Free Radic. Biol. Med. 95, 268–277 (2016). DOI: https://doi.org/10.1016/j.freeradbiomed.2016.03.020
Laffel, L. 1999. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes. Metab. Res. Rev. 15, 412–426 (1999). DOI: https://doi.org/10.1002/(SICI)1520-7560(199911/12)15:6<412::AID-DMRR72>3.0.CO;2-8
Limcharoen, T. et al. 2022. Inhibition of α-Glucosidase and Pancreatic Lipase Properties of Mitragyna speciosa (Korth.) Havil. (Kratom) Leaves. Nutrients 14, 1–15 (2022). DOI: https://doi.org/10.3390/nu14193909
Sapra A, B. P. Diabetes. https://www.ncbi.nlm.nih.gov/books/NBK551501/.
WHO. 2023. Diabetes. https://www.who.int/health-topics/diabetes#tab=tab_1 (2023).
Zailan, N. F. Z., Sarchio, S. N. E. & Hassan, M. 2022. Evaluation of Phytochemical Composition, Antioxidant and anti-Diabetic Activities of Mitragyna speciosa Methanolic Extract (MSME). Malaysian J. Med. Heal. Sci. 18, 92–99 (2022). DOI: https://doi.org/10.47836/mjmhs.18.s21.15
Zhang, P. et al. 2023. Antidiabetic and antioxidant activities of Mitragyna speciosa (kratom) leaf extract in type 2 diabetic rats. Biomed. Pharmacother. 162, 114689 (2023). DOI: https://doi.org/10.1016/j.biopha.2023.114689